Trials / Recruiting
RecruitingNCT07241416
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
A Multicenter, Randomized, Open-Label, Positive-Controlled Phase III Study of Rezvilutamide Combined With Androgen Deprivation Therapy (ADT) Versus Enzalutamide Combined With ADT for Treating Low-volume Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rezvilutamide Tablets | Rezvilutamide tablets, oral administration. |
| DRUG | Enzalutamide Soft Capsules | Enzalutamide soft capsules, oral administration. |
Timeline
- Start date
- 2025-12-05
- Primary completion
- 2027-03-01
- Completion
- 2028-09-01
- First posted
- 2025-11-21
- Last updated
- 2026-01-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07241416. Inclusion in this directory is not an endorsement.